Company intelligence / Profile preview

ENTOD Pharmaceuticals

Mumbai, Maharashtra, Indiaentodpharma.com ↗

Ownership: Private
Employees: ~4999
Development stage: Commercial

Overview

ENTOD has multiple commercial products and recently received marketing authorization for 0.05% atropine eye drops (Myatro XL) for pediatric myopia control in India. They also developed PresVu eye drops for presbyopia and are working on human insulin eye drops for conditions like diabetic retinopathy.

Therapeutic areas: DermatologyOphthalmologyInfectious Diseases
Modalities: Small moleculesOphthalmic formulationsENT formulationsDermatological formulations
Industry: Biotech

Drug pipeline

2 assets

Furwax SA

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Eyecirque Eye, Skin & Mind Wellness (stake ownership)

Beyond the preview

Go deeper on ENTOD Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENTOD Pharmaceuticals.

Explore the full profile